Scholarlink

Background <p>Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) effectively increase hemoglobin levels to treat anemia in patients with chronic kidney disease (CKD). However, there is a paucity of studies on the effect of HIF-PHIs on renal outcomes, such as estimated glomerular filtration rate based on serum creatinine (eGFRcre). Therefore, this study aimed to examine the trajectory of eGFRcre decline following initiation of treatment with HIF-PHI and erythropoiesis-stimulating agents (ESAs) in non-dialysis patients.</p> Methods <p>This single-center, retrospective study enrolled non-dialysis patients who were prescribed HIF-PHIs between January 1, 2020 and December 31, 2022. We used five HIF-PHIs approved in Japan. The eGFRcre slope for a year after HIF-PHIs therapy was initiated was compared with that of ESAs. The eGFRcre slope was calculated using a linear mixed-effects model for repeated measures over a year from the time of enrollment.</p> Results <p>This study included 134 patients: 79 and 55 patients treated with HIF-PHIs and ESAs, respectively. The model adjusting for time, drug (HIF-PHI or ESA), their interaction, age, sex, BMI, and CKD stage showed that the effect on eGFRcre differed between HIF-PHIs and ESAs (−2.11 ± 0.57 mL/min/1.73 m<sup>2</sup> per year vs. −3.27 ± 0.17 mL/min/1.73 m<sup>2</sup> per year, <i>p</i> = 0.046). Subgroup analysis by CKD stage revealed a difference in the eGFRcre slope between HIF-PHI and ESA only in the stage 4 group (−1.89 ± 0.44 mL/min/1.73 m<sup>2</sup> per year vs. −3.69 ± 0.44 mL/min/1.73 m<sup>2</sup> per year, <i>p</i> &lt; 0.001).</p> Conclusions <p>HIF-PHI preserved eGFRcre for a year, suggesting that its effect was superior to that of ESA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preservation of eGFRcre for 1 year with HIF-PHI in non-dialysis patients: a retrospective observational cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月20日

查看全文
  • Tomohiro Aigami,
  • Tomoyuki Ishigo,
  • Mai Miyao,
  • Masatoshi Nonoyama,
  • Tomohisa Yamashita,
  • Masayuki Koyama,
  • Satoshi Fujii,
  • Toshiyuki Yano,
  • Masato Furuhashi,
  • Masahide Fukudo,
  • Takaki Toda

摘要

Background

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) effectively increase hemoglobin levels to treat anemia in patients with chronic kidney disease (CKD). However, there is a paucity of studies on the effect of HIF-PHIs on renal outcomes, such as estimated glomerular filtration rate based on serum creatinine (eGFRcre). Therefore, this study aimed to examine the trajectory of eGFRcre decline following initiation of treatment with HIF-PHI and erythropoiesis-stimulating agents (ESAs) in non-dialysis patients.

Methods

This single-center, retrospective study enrolled non-dialysis patients who were prescribed HIF-PHIs between January 1, 2020 and December 31, 2022. We used five HIF-PHIs approved in Japan. The eGFRcre slope for a year after HIF-PHIs therapy was initiated was compared with that of ESAs. The eGFRcre slope was calculated using a linear mixed-effects model for repeated measures over a year from the time of enrollment.

Results

This study included 134 patients: 79 and 55 patients treated with HIF-PHIs and ESAs, respectively. The model adjusting for time, drug (HIF-PHI or ESA), their interaction, age, sex, BMI, and CKD stage showed that the effect on eGFRcre differed between HIF-PHIs and ESAs (−2.11 ± 0.57 mL/min/1.73 m2 per year vs. −3.27 ± 0.17 mL/min/1.73 m2 per year, p = 0.046). Subgroup analysis by CKD stage revealed a difference in the eGFRcre slope between HIF-PHI and ESA only in the stage 4 group (−1.89 ± 0.44 mL/min/1.73 m2 per year vs. −3.69 ± 0.44 mL/min/1.73 m2 per year, p < 0.001).

Conclusions

HIF-PHI preserved eGFRcre for a year, suggesting that its effect was superior to that of ESA.